SCHOLAR ROCK HOLDING CORPORATION Contract with Customer, Liability, Noncurrent
SCHOLAR ROCK HOLDING CORPORATION (SRRK) had Contract with Customer, Liability, Noncurrent of $33.19 million as of 2020-12-31, per its 10-K filed 2022-03-07.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:ContractWithCustomerLiabilityNoncurrent · last filed 2022-03-07
- 2020-12-31: Contract with Customer, Liability, Noncurrent $33.19M.
- 2020-09-30: Contract with Customer, Liability, Noncurrent $38.74M.
- 2020-06-30: Contract with Customer, Liability, Noncurrent $38.12M.
- 2020-03-31: Contract with Customer, Liability, Noncurrent $46.11M.
| Period end | Contract with Customer, Liability, Noncurrent |
|---|---|
| 2020-12-31 | $33.19M 10-K · filed 2022-03-07 |
| 2020-09-30 | $38.74M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $38.12M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $46.11M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $46.49M 10-K · filed 2021-03-09 |
| 2019-09-30 | $29.73M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $31.23M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $34.43M 10-Q · filed 2019-05-15 |
| 2018-12-31 | $42.70M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |